Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and ...

Teva Pharmaceuticals continues to beat consensus estimates, has once again raised its 2025 financial guidance and secured ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amphastar ...

Morgan Stanley maintained an 'overweight' rating on ITC Ltd. with a target price of Rs 500, citing strong topline growth ...